Sanofi's Lunsekimig Meets Phase 2 Endpoints in Asthma and CRSwNP, Bolstering Respiratory Pipeline
summarizeSummary
Sanofi announced positive Phase 2 results for its novel bispecific Nanobody, lunsekimig, in two chronic respiratory diseases. The drug met primary and key secondary endpoints in studies for moderate-to-severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), demonstrating significant reductions in exacerbations and improved lung function. While an exploratory Phase 2b study in atopic dermatitis did not meet its primary endpoint, improvements were observed in key secondary endpoints. This success for lunsekimig, which targets both TSLP and IL-13, significantly de-risks a key pipeline asset and reinforces Sanofi's long-term growth potential in respiratory therapeutics. This follows recent positive news for other Sanofi pipeline assets, indicating continued R&D momentum. Investors will be watching for detailed data presentations at upcoming medical congresses and progress in its ongoing Phase 3 studies.
At the time of this announcement, SNY was trading at $47.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.5B. The 52-week trading range was $43.32 to $55.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.